Synergy Pharma (SGYP) reported Q4 numbers that deviated from guidance in a positive manner. The investment thesis in the stock is further enhanced that better transparency from management would've prevented the crash in the stock to new lows below $2 in the first place.
Positive Cash Flow Steps
The biggest issue with Synergy Pharma over the last several months was the perplexing statement by the CFO that Q4 cash flows would match the roughly $60 million burn rate for the 1H of last year. As revenues were growing and R&D spending was set to drop, the numbers never added up as the biotech would only burn another $60 million during the December quarter from a massive inventory build.

